6Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C- reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease [J 1. Circulation, 2000, 102(9): 1000-6.
7Yasmin, Carmel M, McEniery, et al. C-Reactive Protein Is Associated With Arterial Stiffiaess in Apparently Healthy Individuals [J].Arterioscler Thromb Vasc Biol, 2004, 24(5): 969-74.
8Asmar R, Topouchian J, PannierB, et al. Pulse wave velocity as endpoint in large - scale intervention trial. The Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study[J]. J Hypertens, 2001, 19 (4): 813-8.
9Bautista LE, Lopez-Jaramillo P, Vera LM, et al. C-reactive protein is an independent risk factor for essential hypertension [ J ]. Hypertens, 2001, 19(5): 875-61.
10Sung KC, Sub JY, Kim BS, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension[J].Am J Hypertens, 2003, 16(6): 429-33.
6Ishii H, Tsukada T, Yoshida M. Angiotensin Ⅱ type- Ⅰ receptor blocker, candesartan, improves brachial-ankle pulse wave velocity independent of its blood pressure lowering effects in type 2 diabetes patients[J]. Intern Med, 2008,47 (5) : 2013-2015.
7Vicente I, Lahoz C, Taboada M, et al. Prevalence of an abnormal ankle-brachial index in relation to the cardiovascular risk estimated by the Framingham function [J]. Med Clin (Barc), 2005,124(17) :641-644.
8Murabito JM, Evans JC, Larson MG, et al. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: The Framingham study [J]. Arch Intern Med, 2003,163 (16):1939-1942.
9Ostergren J, Sleight P, Dagenais K, etal. Impact of rampril in patients with evidence of 24 clinical or subclinical peripheral arterial disease[J]. Eur Heart J, 2004,25 (1) : 17-24.
10McDremott MM, Liu K, Criqui MH, et al. Ankle-brachial index and subclinical cardiac and carotid disease: (the multi-ethnic study atherosclerosis) [J]. Am J Epidemiol, 2005, 162 (1) 33-41.
